About Lytix Biopharma ASdeveloped Lytix Biopharma AS novel drugs for the treatment of resistant bacterial and fungal infections as well as first-in – class oncology treatments. – are operating system from a main office in Tromso and through our continued collaboration with the University of Tromso the access to access to state-of – the-art laboratories and staff with extensive experience in the development of peptide-based drugs, including preparation of peptidomimetic. Business and product development of the office in Oslo driven.
Effective against a wide presented LTX-109 Anti-Microbial at ICAAC – The Scandinavian – based drug development company Lytix Biopharma has announced the results of studies on its lead antimicrobial candidate LTX-109. Presented at ICAAC in Washington, the studies showed that the novel lytic peptidomimetic ultra fast bactericidal effect, much better at killing Staphylococcus aureus and Streptococcus pyogenes than marketed gold standard drug has. Moreover, it has proven to be effective against a wide range of 110 European clinical isolates of Pseudomonas aeruginosa, a gram problrmatic effective bacteria.Clementina Mumba, chairman of the Treatment Advocacy and Literacy Campaign said the candidates remained to HIV / AIDS problem due to the stigma associated with with the disease are silent. Said: I said: I am surprised not a single politician has stated he is HIV-positive , not even a Ministerial or legislator has done that The one image the HIV / AIDS only infects of the poor portraits. added: added: During the presidential campaign, does not a single candidate has said what you will to tackle HIV / AIDS. .
Reuters reported Many of the Zambian public about future of of the struggle against HIV / AIDS after presidential elections, Reuters reports.